Oncology peptides
Peptide Design for Cancer Therapy and Tumor Targeting
Peptides offer unique advantages in oncology — the ability to target tumor-specific receptors, penetrate solid tumors, and deliver cytotoxic payloads with precision. Designing oncology peptides that combine tumor selectivity with therapeutic potency requires integrating target biology, structural analysis, and computational design. We support peptide cancer therapy programs from target identification through development candidate selection.
The Oncology Peptide Design Challenge
Cancer therapy demands high selectivity — therapeutic peptides must distinguish tumor cells from healthy tissue. Achieving this selectivity while maintaining potency, stability in the tumor microenvironment, and adequate tumor penetration is a multidimensional design problem.
Computational methods that integrate tumor receptor biology, structural data, and property prediction allow more systematic exploration of the oncology peptide design space — enabling faster identification of candidates with the right combination of selectivity, potency, and developability.
Our Oncology Peptide Approach
Tumor receptor targeting
Design of peptides targeting overexpressed tumor receptors — integrins, growth factor receptors, tumor-specific antigens — with high selectivity.
Tumor microenvironment optimization
Engineering for stability and activity in the acidic, protease-rich tumor microenvironment.
Payload conjugation design
Optimization of peptide-drug conjugate (PDC) linker chemistry and payload attachment for tumor-selective delivery.
Penetration and distribution modeling
Computational analysis of tumor penetration, distribution, and retention for solid tumor applications.
Oncology Peptide Discovery Workflow
Target and tumor type specification
Define the tumor type, target receptor or pathway, and therapeutic objective.
Target analysis
Structural and expression analysis of the tumor target to define design constraints.
Candidate design
AI-assisted generation of tumor-targeting peptide candidates.
Selectivity and potency prediction
Computational assessment of tumor selectivity, binding affinity, and cytotoxic potential.
Experimental validation
Cell-based and in vivo validation of priority candidates.
Development candidate selection
Selection of candidates meeting oncology development criteria.
What Can Be Evaluated
What You May Receive
Tumor-targeting peptide candidates
Designed sequences with predicted receptor affinity, selectivity, and stability profiles.
Selectivity analysis report
Computational assessment of tumor versus normal tissue selectivity for priority candidates.
PDC design strategy
Recommended linker chemistry and payload attachment approach for peptide-drug conjugate programs.
Development roadmap
Path from initial candidates to an oncology development candidate.
Deliverables depend on project scope and tumor type. Antitumor activity cannot be guaranteed computationally.
Who This Is For
Oncology researchers
Academic groups studying tumor biology and developing peptide-based tools or therapeutic leads.
Biotech companies
Companies developing tumor-targeting peptides, peptide-drug conjugates, or peptide-based cancer immunotherapies.
Pharmaceutical oncology teams
Drug discovery teams exploring peptide modalities for oncology targets.
Frequently Asked Questions
Design Peptides for Cancer Therapy
Submit your tumor target and oncology program objectives. We will assess the peptide design opportunity and outline a discovery approach for your cancer therapy program.
Confidential program discussions available under NDA.